세계의 만성 유연증 시장 보고서(2025년)

Chronic Sialorrhea Global Market Report 2025

US $ 4,490 ￦ 6,684,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,662,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,639,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

만성 유연증 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 예측 기간 동안의 성장은 치료 옵션에 대한 인식 제고, 효과적인 치료법에 대한 필요성 증가, 의료비 지출 증가, 소아 환자 증가, 구강 젤 및 액제에 대한 수요 증가와 같은 요인에 기인할 수 있습니다. 이 기간에 예상되는 주요 동향에는 원격 모니터링을 위한 원격 의료의 이용, 환자 중심의 케어 모델, 약리학의 혁신, 언어 치료와 작업 치료의 통합, 장시간 작용형 의약품의 개발 등이 있습니다.

신경 퇴행성 질환의 유병률이 증가하면 만성 유연증 시장의 성장을 견인할 것으로 예측됩니다. 만성 유연증은 파킨슨병 및 루게릭병과 같은 질환에서 흔히 발생하는 합병증으로, 흡인을 예방하고 구강 기능을 개선하며 환자의 편안함을 향상시키기 위한 특별한 치료가 필요합니다. 예를 들어, 2023년 9월 영국 파킨슨병 협회(Parkinson's UK)는 영국에서 약 15만 3,000명이 파킨슨병을 앓았으며 인구 고령화로 인해 2030년에는 이 수가 20% 증가하여 약 17만 2,000명이 될 것으로 예상한다고 보고했습니다.

만성 유연증 시장 진출기업은 환자의 컴플라이언스를 향상시키고, 어린이의 만성 유연증을 관리하기 위한 비 침습적인 옵션을 제공하고, 안전성을 높이고 부작용을 줄이기 위해 경구용 액 등의 혁신적인 치료법의 개발에 주력하고 있습니다. 예를 들어, 2023년 2월 영국에 본사를 둔 제약 회사인 Proveca Pharma Ltd.는 신경 장애가 있는 어린이의 중증 만성 유연증 치료를 위해 프랑스에서 시알라나(글리코피로니움 브로마이드)를 출시했습니다. 이 제품은 액상 형태로 제공되므로 투여가 간편하고 정확한 용량을 투여할 수 있어 고형 약물을 복용하기 어려운 소아 환자에게 특히 유용합니다. 시알라나는 입증된 안전성과 효능 프로파일을 제공하며, 뇌성마비와 같은 신경 발달 질환에서 흔히 나타나는 과도한 침 흘림을 줄여 삶의 질을 개선합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 만성 유연증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 만성 유연증 시장 : 성장률 분석
• 세계의 만성 유연증 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 만성 유연증 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 만성 유연증 전체 시장(TAM)

제6장 시장 세분화

• 세계의 만성 유연증 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 약물 치료
• 보툴리눔 주사
• 외과적 개입
• 의료기기 및 보조요법
• 세계의 만성 유연증 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 경구용 약물
• 주사제 치료
• 국소 적용
• 세계의 만성 유연증 시장 : 환자 집단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 소아 환자
• 성인 환자
• 세계의 만성 유연증 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 및 전문 클리닉
• 재활센터
• 재택 케어
• 세계의 만성 유연증 시장 : 약물 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 항콜린제
• 항우울제
• 알파 아드레날린 작용제
• 타액선 조절제
• 세계의 만성 유연증 시장 : 보툴리눔 주사 주사 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 보툴리눔 주사 A형(보톡스)
• 보툴리눔 주사 B형(미오블록)
• 국소 침샘 주사제
• 세계의 만성 유연증 시장 : 외과적 개입 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 침샘 내시경 검사
• 침샘관 확장술 또는 스텐트 삽입술
• 이하선관 수술
• 턱밑샘 절제술(타액샘 절제술)
• 세계의 만성 유연증 시장 : 의료기기 및 보조요법 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 구강 건조증 장치
• 타액 자극 장치
• 입술 및 구강 운동
• 인공 침샘

제7장 지역별/국가별 분석

• 세계의 만성 유연증 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 만성 유연증 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 만성 유연증 시장 : 경쟁 구도
• 만성 유연증 시장 : 기업 프로파일
  • Pfizer Inc.
  • Eisai Co. Ltd.
  • Ipsen Pharmaceuticals Inc.
  • Aurobindo Pharma Limited
  • Shionogi Inc.

제31장 기타 주요 기업 및 혁신 기업

• Supernus Pharmaceuticals Inc.
• Granules India Limited
• Hugel Inc.
• Medy-Tox Inc.
• Gufic Biosciences Limited
• US WorldMeds LLC
• Proveca Limited
• Neos Therapeutics Inc.
• Merz Therapeutics GmbH
• Taj Pharma India Limited
• Meitheal Pharmaceuticals
• Clini Experts Services Private Limited
• NeuroHealing Pharmaceuticals Inc.
• ExCEEd Orphan Pharmaceuticals AG
• Solstice Neurosciences Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

• 만성 유연증 시장(2029년) : 새로운 기회를 제공하는 국가
• 만성 유연증 시장(2029년) : 새로운 기회를 제공하는 부문
• 만성 유연증 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

Chronic sialorrhea refers to the ongoing excessive production or inability to control saliva, commonly linked to neurological disorders such as Parkinson's disease, cerebral palsy, or ALS. Treatment options include pharmacological therapies, botulinum toxin injections, and surgical procedures aimed at improving oral function, minimizing complications, and enhancing patients' quality of life.

The primary treatment options for chronic sialorrhea are pharmacological therapies, botulinum toxin injections, surgical procedures, medical devices, and assistive therapies. Pharmacological treatments typically involve medications, such as anticholinergics and botulinum toxin injections, to reduce excessive saliva production and alleviate symptoms. These treatments can be administered in various forms, including oral medications, injections, and topical treatments. The patient population for these therapies spans both pediatric and adult groups, with key end users including hospitals, specialty clinics, rehabilitation centers, and homecare environments.

The chronic sialorrhea market research report is one of a series of new reports from The Business Research Company that provides chronic sialorrhea market statistics, including the chronic sialorrhea industry global market size, regional shares, competitors with the chronic sialorrhea market share, detailed chronic sialorrhea market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic sialorrhea industry. This chronic sialorrhea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic sialorrhea market size has grown strongly in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to factors such as the rising prevalence of neurological disorders, population growth, greater awareness and diagnosis, and an increasing demand for non-invasive treatments.

The chronic sialorrhea market size is expected to see strong growth in the next few years. It will grow to $0.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period can be attributed to factors such as greater awareness of treatment options, a rising need for effective therapies, increased healthcare spending, growing pediatric cases, and higher demand for oral gels and liquids. Key trends expected in this period include the use of telemedicine for remote monitoring, patient-centered care models, innovations in pharmacology, the integration of speech and occupational therapies, and the development of long-acting pharmaceuticals.

The rising prevalence of neurodegenerative disorders is expected to drive the growth of the chronic sialorrhea market. Neurodegenerative disorders are a group of diseases characterized by the gradual degeneration or death of neurons in the brain and spinal cord. The increase in these disorders is influenced by factors such as genetics, family history, environmental influences, a better understanding of disease mechanisms, chronic health conditions, and social and psychological factors. Chronic sialorrhea is a common complication in conditions such as Parkinson's disease and ALS, requiring specific treatments to prevent aspiration, improve oral function, and enhance patient comfort. For example, in September 2023, Parkinson's UK reported that around 153,000 individuals in the UK are living with Parkinson's disease, and with the aging population, this number is expected to rise by 20% to an estimated 172,000 by 2030. The growing prevalence of neurodegenerative disorders will, therefore, contribute to the expansion of the chronic sialorrhea market.

Companies operating in the chronic sialorrhea market are focusing on developing innovative treatments such as oral solutions to improve patient compliance and provide non-invasive options for managing chronic sialorrhea in children, enhancing safety and reducing side effects. Oral solutions are liquid medications formulated for easy ingestion, with the active ingredient dissolved in a solvent. For instance, in February 2023, Proveca Pharma Ltd., a UK-based pharmaceutical company, launched Sialanar (glycopyrronium bromide) in France for the treatment of severe chronic sialorrhea in children with neurological disorders. This product is available in a liquid form, making it easier to administer and ensuring accurate dosing, which is especially beneficial for pediatric patients who may have difficulty with solid medications. Sialanar offers a proven safety and efficacy profile, improving the quality of life by reducing excessive drooling, a common issue in neurodevelopmental conditions such as cerebral palsy.

In March 2022, Proveca Pharma Ltd. partnered with ExCEEd Orphan to distribute and commercialize Sialanar exclusively in Central and Eastern Europe. This collaboration aims to make Sialanar more widely available for treating chronic sialorrhea in children with neurodisabilities across eight countries in the region. The partnership addresses an unmet medical need and helps improve the quality of life for patients struggling with excessive drooling due to neurological disorders. ExCEEd Orphan S.R.O., based in the Czech Republic, specializes in helping patients with rare diseases, such as chronic sialorrhea.

Major players in the chronic sialorrhea market are Pfizer Inc., Eisai Co. Ltd., Ipsen Pharmaceuticals Inc., Aurobindo Pharma Limited, Shionogi Inc., Supernus Pharmaceuticals Inc., Granules India Limited, Hugel Inc., Medy-Tox Inc., Gufic Biosciences Limited, US WorldMeds LLC, Proveca Limited, Neos Therapeutics Inc., Merz Therapeutics GmbH, Taj Pharma India Limited, Meitheal Pharmaceuticals, Clini Experts Services Private Limited, NeuroHealing Pharmaceuticals Inc., ExCEEd Orphan Pharmaceuticals AG, and Solstice Neurosciences Inc.

North America was the largest region in the chronic sialorrhea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic sialorrhea report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic sialorrhea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic sialorrhea market consists of revenues earned by entities by providing services such as medical treatment services, non-surgical interventions, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic sialorrhea market also includes sales of neurostimulation devices, resection kits, absorbent clothing and bibs, and customized oral prosthetics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Sialorrhea Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic sialorrhea market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic sialorrhea ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic sialorrhea market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Pharmacological Treatments; Botulinum Toxin Injections; Surgical Interventions; Medical Devices And Assistive Therapies
• 2) By Route Of Administration: Oral Medications; Injectable Treatments; Topical Applications
• 3) By Patient Population: Pediatric Patients; Adult Patients
• 4) By End-User: Hospitals And Specialty Clinics; Rehabilitation Centers; Homecare Settings
• Subsegments:
• 1) By Pharmacological Treatments: Anticholinergic Medications; Antidepressants; Alpha-adrenergic Agonists; Salivary Gland Modulators
• 2) By Botulinum Toxin Injections: Botulinum Toxin Type A (Botox); Botulinum Toxin Type B (Myobloc); Localized Salivary Gland Injections
• 3) By Surgical Interventions: Sialendoscopy; Salivary Gland Duct Dilation or Stenting; Parotid Duct Surgery; Submandibular Gland Removal (Sialadenectomy)
• 4) By Medical Devices And Assistive Therapies: Oral Dryness Devices; Salivary Stimulation Devices; Lip and Mouth Exercises; Artificial Salivary Glands
• Companies Mentioned: Pfizer Inc.; Eisai Co. Ltd.; Ipsen Pharmaceuticals Inc.; Aurobindo Pharma Limited; Shionogi Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Sialorrhea Market Characteristics

3. Chronic Sialorrhea Market Trends And Strategies

4. Chronic Sialorrhea Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Chronic Sialorrhea Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Sialorrhea PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Sialorrhea Market Growth Rate Analysis
• 5.4. Global Chronic Sialorrhea Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Sialorrhea Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Sialorrhea Total Addressable Market (TAM)

6. Chronic Sialorrhea Market Segmentation

• 6.1. Global Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacological Treatments
• Botulinum Toxin Injections
• Surgical Interventions
• Medical Devices And Assistive Therapies
• 6.2. Global Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Medications
• Injectable Treatments
• Topical Applications
• 6.3. Global Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Patients
• Adult Patients
• 6.4. Global Chronic Sialorrhea Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Specialty Clinics
• Rehabilitation Centers
• Homecare Settings
• 6.5. Global Chronic Sialorrhea Market, Sub-Segmentation Of Pharmacological Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anticholinergic Medications
• Antidepressants
• Alpha-adrenergic Agonists
• Salivary Gland Modulators
• 6.6. Global Chronic Sialorrhea Market, Sub-Segmentation Of Botulinum Toxin Injections, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Botulinum Toxin Type A (Botox)
• Botulinum Toxin Type B (Myobloc)
• Localized Salivary Gland Injections
• 6.7. Global Chronic Sialorrhea Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sialendoscopy
• Salivary Gland Duct Dilation or Stenting
• Parotid Duct Surgery
• Submandibular Gland Removal (Sialadenectomy)
• 6.8. Global Chronic Sialorrhea Market, Sub-Segmentation Of Medical Devices And Assistive Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Dryness Devices
• Salivary Stimulation Devices
• Lip and Mouth Exercises
• Artificial Salivary Glands

7. Chronic Sialorrhea Market Regional And Country Analysis

• 7.1. Global Chronic Sialorrhea Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Sialorrhea Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Sialorrhea Market

• 8.1. Asia-Pacific Chronic Sialorrhea Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Sialorrhea Market

• 9.1. China Chronic Sialorrhea Market Overview
• 9.2. China Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Sialorrhea Market

• 10.1. India Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Sialorrhea Market

• 11.1. Japan Chronic Sialorrhea Market Overview
• 11.2. Japan Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Sialorrhea Market

• 12.1. Australia Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Sialorrhea Market

• 13.1. Indonesia Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Sialorrhea Market

• 14.1. South Korea Chronic Sialorrhea Market Overview
• 14.2. South Korea Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Sialorrhea Market

• 15.1. Western Europe Chronic Sialorrhea Market Overview
• 15.2. Western Europe Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Sialorrhea Market

• 16.1. UK Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Sialorrhea Market

• 17.1. Germany Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Sialorrhea Market

• 18.1. France Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Sialorrhea Market

• 19.1. Italy Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Sialorrhea Market

• 20.1. Spain Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Sialorrhea Market

• 21.1. Eastern Europe Chronic Sialorrhea Market Overview
• 21.2. Eastern Europe Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Sialorrhea Market

• 22.1. Russia Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Sialorrhea Market

• 23.1. North America Chronic Sialorrhea Market Overview
• 23.2. North America Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Sialorrhea Market

• 24.1. USA Chronic Sialorrhea Market Overview
• 24.2. USA Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Sialorrhea Market

• 25.1. Canada Chronic Sialorrhea Market Overview
• 25.2. Canada Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Sialorrhea Market

• 26.1. South America Chronic Sialorrhea Market Overview
• 26.2. South America Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Sialorrhea Market

• 27.1. Brazil Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Sialorrhea Market

• 28.1. Middle East Chronic Sialorrhea Market Overview
• 28.2. Middle East Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Sialorrhea Market

• 29.1. Africa Chronic Sialorrhea Market Overview
• 29.2. Africa Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Sialorrhea Market Competitive Landscape And Company Profiles

• 30.1. Chronic Sialorrhea Market Competitive Landscape
• 30.2. Chronic Sialorrhea Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Ipsen Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Shionogi Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Sialorrhea Market Other Major And Innovative Companies

• 31.1. Supernus Pharmaceuticals Inc.
• 31.2. Granules India Limited
• 31.3. Hugel Inc.
• 31.4. Medy-Tox Inc.
• 31.5. Gufic Biosciences Limited
• 31.6. US WorldMeds LLC
• 31.7. Proveca Limited
• 31.8. Neos Therapeutics Inc.
• 31.9. Merz Therapeutics GmbH
• 31.10. Taj Pharma India Limited
• 31.11. Meitheal Pharmaceuticals
• 31.12. Clini Experts Services Private Limited
• 31.13. NeuroHealing Pharmaceuticals Inc.
• 31.14. ExCEEd Orphan Pharmaceuticals AG
• 31.15. Solstice Neurosciences Inc.

32. Global Chronic Sialorrhea Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Sialorrhea Market

34. Recent Developments In The Chronic Sialorrhea Market

35. Chronic Sialorrhea Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Sialorrhea Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Sialorrhea Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Sialorrhea Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료